Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents. This is an ASCO Meeting Abstract ...

Lutathera was approved for patients 12 or older with SSTR-positive gastroenteropancreatic neuroendocrine tumors, the FDA announced. The Food and Drug Administration (FDA) approved Lutathera (lutetium ...

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial ...

SAN FRANCISCO -- Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a ...

Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles. This is an ASCO Meeting Abstract from the ...

SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline ...

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial ...

Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...

If you or a loved one has gastroenteropancreatic neuroendocrine tumors (GEP-NETs), you may be interested in learning about treatment options. One medicine you might hear about is Lutathera (lutetium ...

Sanofi and Orana Med’s radiopharmaceutical candidate has met all its primary endpoints in a Phase II trial, meaning the former’s €320m bet on the therapy looks to be paying off. In the ongoing ...

MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026 Molecular Targeting Technologies, ...

If you have gastroenteropancreatic neuroendocrine tumors (GEP-NETs), adopting healthy lifestyle habits such as eating right and exercising can help you stay well during treatment. Unlike other cancers ...